Evaluating the effect of atorvastatin exposure and vitamin D levels on lipid outcomes in people with <scp>HIV</scp> ‐1 with suppressed <scp>HIV</scp> ‐1 <scp>RNA</scp> and <scp>LDL</scp> cholesterol <130 mg/ <scp>dL</scp>-Reference-Cited by-同舟云学术

Evaluating the effect of atorvastatin exposure and vitamin D levels on lipid outcomes in people with HIV ‐1 with suppressed HIV ‐1 RNA and LDL cholesterol <130 mg/ dL

Published:2022-12-22 Issue: Volume: Page:
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Medicine

Author:

Rahman Farah¹^ORCID,Brates Irena²,Aweeka Francesca³,Bosch Ronald J.²,Deitchman Amelia³,Nixon Daniel⁴,Aberg Judith A.¹

Affiliation:

1. Department of Medicine, Division of Infectious Diseases Icahn School of Medicine at Mount Sinai New York New York USA

2. Center for Biostatistics and Research Harvard School of Public Health Boston Massachusetts USA

3. Department of Clinical Pharmacy University of California San Francisco California USA

4. Department of Medicine, School of Medicine Virginia Commonwealth University Richmond Virginia USA

Funder

Pfizer Pharmaceuticals

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hiv.13453

Reference17 articles.

1. Increase acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease;Triant VA;J Clin Endocrinol Metab,2007

2. HIV infection and the risk of acute myocardial infarction;Freiberg MS;JAMA Intern Med,2013

3. Effect of statins on atherosclerotic plaque

4. NixonD AbergJ BoschR et al.Effects of atorvastatin on biomarkers of immune activation inflammation and lipids in virologically suppressed human immunodeficiency virus‐1‐infected individuals with low‐density lipoprotein cholesterol.

5. Vitamin D and Cardiovascular Disease: Current Evidence and Future Perspectives